# ARTACUS (NCT04349436)

> Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04349436
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Replimune, Inc.
- Conditions: Merkel Cell Carcinoma; Basal Cell Carcinoma; Locally Advanced Cutaneous Squamous Cell Carcinoma; Cancer
- Interventions: RP1, intra-tumoral injection, oncolytic virus
- Enrollment: 69
- Primary outcome: Primary Objective for Patients with Locally Advances CSCC (laCSCC)
- Primary outcome: Primary Efficacy Objective for Patients with Other Skin Cancers
- Primary outcome: Primary Safety Objective for Patients with Other Skin Cancers

## Commentary we found

- YouTube: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=artacus-nct04349436